Spero Therapeutics, Inc. Net Cash Provided by (Used in) Operating Activities, Continuing Operations
Spero Therapeutics, Inc. (SPRO) reported Net Cash Provided by (Used in) Operating Activities, Continuing Operations of -$11.96 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-10.
Discontinued › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations · last filed 2018-05-10
- Spero Therapeutics, Inc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2018-03-31 was -$11.96M.
- Spero Therapeutics, Inc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2017-12-31 was -$12.74M.
- Spero Therapeutics, Inc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2017-03-31 was -$6.98M.
- Spero Therapeutics, Inc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2016-12-31 was -$9.20M.
- Spero Therapeutics, Inc. net cash provided by (used in) operating activities, continuing operations for fiscal 2017 was -$39.11M.
- Spero Therapeutics, Inc. net cash provided by (used in) operating activities, continuing operations for fiscal 2016 was -$28.96M.
- Spero Therapeutics, Inc. net cash provided by (used in) operating activities, continuing operations for fiscal 2015 was -$9.61M.
| Period end | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2018-03-31 | -$11.96M 10-Q · filed 2018-05-10 | -$24.70M derived: sum of 2 quarters · filed 2018-05-10 | ||
| 2017-12-31 | -$12.74M derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | -$39.11M 10-K · filed 2018-04-02 | ||
| 2017-09-30 | -$26.37M 10-Q · filed 2017-12-14 | |||
| 2017-03-31 | -$6.98M 10-Q · filed 2018-05-10 | -$16.18M derived: sum of 2 quarters · filed 2018-05-10 | ||
| 2016-12-31 | -$9.20M derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | -$28.96M 10-K · filed 2018-04-02 | ||
| 2016-09-30 | -$19.75M 10-Q · filed 2017-12-14 | |||
| 2015-12-31 | -$9.61M 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |